|
|
|
|
|
HONG KONG, Feb 1, 2023 - (ACN Newswire) - Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that OT-101 (0.01% atropine sulfate eye drop), a self-developed new drug to treat the progression of myopia in children, has completed the enrollment of 170 patients in China for the global phase III randomized, double-masked, placebo-controlled, parallel-group, multicenter clinical trial on January 18, 2023.
The phase III clinical trial of OT-101 is the world's first multi-regional phase III clinical trial for low-concentration atropine and its analogs that includes the Chinese population. To date, no low-concentration atropine ophthalmic preparations have been commercialized in the global mainstream pharmaceutical market.
OT-101 (0.01% atropine sulfate eye drop) is a low-concentration (0.01%) atropine eye drop developed to retard, or slow down, the progression of myopia in children and adolescents, which is the only Anticholinergic medication to date that has been demonstrated to be consistently effective and safe in controlling myopic progression. However, the instability of low-concentration atropine solutions has long been a technical barrier to commercialization. In response to these obstacles, OT-101 uses an innovative closed-loop split device with an exclusive design.
Mr. Ye LIU, the Executive Director and CEO of Ocumension Therapeutics said, "The Group has made improvements to the reliability, closure integrity and sterility conditions of the device, so that it can be as close as possible to the current medication environment for the preparations of low-concentration atropine for use in the hospital, thus solving the stability problem of low-concentration atropine solution in a neutral environment. Also, the appropriate pH value improves the comfort of patients being treated and medication compliance. We believes that the technical breakthroughs in response to the stability issue of low-concentration (0.01%) atropine will be its core competitiveness."
More information about Ocumension Therapeutics: https://www.ocumension.com/
Topic: Press release summary
Source: Ocumension Therapeutics
Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
